Karnataka HC stays action against drug units making Nutraceuticals
Karnataka High Court has directed the government to refrain from taking any action against companies manufacturing nutraceuticals in units licensed for drug production until its next hearing, in a significant relief for the pharmaceutical industry.
ET Year-end Special Reads
Top 10 equity mutual funds of the year. Do you have any?
How India flexed its global power muscles in 2024
2024 was the year India became the talk of America
The newly notified Schedule M proposes a blanket ban on manufacturing of any other article or product apart from drugs in the same facility.
«Till the next date of hearing, the respondents shall not take any precipitative action against the petitioner in so far as it relates to manufacturing of nutraceuticals within the drug manufacturing premises,» the court said.
Federation of Pharma Enterprises (FoPE), which represents medium and small-scale drug companies, along with Karnataka Drugs and Pharmaceutical Manufacturers Association and others had approached the court challenging the Schedule M, arguing that setting up new plant exclusively for cosmetic manufacturing is financially not viable.
They pleaded that drug facilities be permitted to manufacture nutraceuticals in the area dedicated for making topical products such as external preparations such as creams and lotions.
Web Development
Advanced C++ Mastery: OOPs and Template Techniques
By — Metla Sudha Sekhar, IT Specialist and Developer
Marketing
Digital Marketing Masterclass by Pam Moore
By — Pam Moore, Digital Transformation and Social
